Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of hydroxyurea and methotrexate for recurrent Langerhans cell histiocytosis
jRCTs031220324Recruiting
- Sponsor
- National Center for Child Health and Development
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxyurea and methotrexate in Langerhans cell histiocytosis (LCH), sponsored by National Center for Child Health and Development. Primary endpoint: Rate of achieving Non-Active Disease (NAD) at 24 weeks. Started Sep 2022; status: recruiting.
02
Drugs
hydroxyureamethotrexate
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on jRCTs031220324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220324.